Neurol. praxi. 2025;26(3):244-248 | DOI: 10.36290/neu.2025.048

Can I drive a truck? - very late-onset Friedreich's ataxia

MUDr. Kristýna Janotová, MUDr. Zdeněk Kunáš, doc. MUDr. Svatopluk Ostrý, Ph.D.
Neurologické oddělení Nemocnice České Budějovice, a. s.
Neurochirurgická a neuroonkologická klinika 1. lékařská fakulta Univerzita Karlova v Praze a Ústřední vojenská nemocnice - Vojenská fakultní nemocnice Praha

Friedreich's Ataxia (FA) is a rare, genetically inherited multisystem disorder that ranks among the most common hereditary ataxias. The initial symptoms typically manifest during adolescence, and within approximately ten years, the disease often leads to fatal disability. However, this case report discusses a rare atypical form with late onset in adulthood. Diagnosing late-onset forms is particularly challenging due to their more variable phenotypic presentation and slower progression compared to the classic form. Accurate diagnosis of FA in patients with chronic ataxic symptoms has gained renewed importance, especially in light of the first approved treatment available on the Czech market since 2024. This therapy not only improves symptoms but also has the potential to slow disease progression. Therefore, it is crucial to consider Friedreich's ataxia in the differential diagnosis and to recommend genetic testing when suspected, as it is essential for definitive diagnosis.

Keywords: Friedreich's ataxia, late-onset and very late-onset form, diagnostics, omaveloxolone, genetic screening.

Received: May 5, 2025; Revised: May 29, 2025; Accepted: May 29, 2025; Prepublished online: May 29, 2025; Published: July 4, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Janotová K, Kunáš Z, Ostrý S. Can I drive a truck? - very late-onset Friedreich's ataxia. Neurol. praxi. 2025;26(3):244-248. doi: 10.36290/neu.2025.048.
Download citation
PDF will be unlocked 4.7.2026

References

  1. . Andermann F. Nicolaus Friedreich and degenerative atrophy of the posterior columns of the spinal cord. Can J Neurol Sci. 1976;3(4):275-7. doi: 10.1017/s0317167100025452. Go to original source... Go to PubMed...
  2. . Bidichandani SI, Delatycki MB, Napierala M, et al. Friedreich Ataxia. In: Adam MP, Feldman J, Mirzaa GM, et al. GeneReviews®. Seattle (WA): University of Washington, Seattle; December 18, 1998.
  3. . Campuzano V, Montermini L, Moltò MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271(5254):1423-7. doi: 10.1126/science.271.5254.1423. Go to original source... Go to PubMed...
  4. . Dayalan Naidu S, Dinkova-Kostova AT. Omaveloxolone (SkyclarysTM) for patients with Friedreich's ataxia. Trends Pharmacol Sci. 2023;44(6):394-395. doi: 10.1016/j.tips.2023.03.005. Go to original source... Go to PubMed...
  5. . Delatycki MB, Corben LA, Maria BL. Clinical Features of Friedreich Ataxia. J Child Neurol.ens. 2012;27(9):1133-1137. doi:10.1177/0883073812448230. Go to original source... Go to PubMed...
  6. Fearon C, Lonergan R, Ferguson D, et al. Very-late-onset Friedreich's ataxia: diagnosis in a kindred with late-onset cerebellar ataxia. Pract Neurol. 2020;20(1):55-58. doi:10.1136/practneurol-2019-002368 Go to original source... Go to PubMed...
  7. . Keita M, McIntyre K, Rodden LN, et al. Friedreich ataxia: clinical features and new developments. Neurodegener Dis Manag. 2022;12(5):267-283. doi: 10.2217/nmt-2022-0011 Go to original source... Go to PubMed...
  8. . La Rosa P, Petrillo S, Turchi R, et al. The Nrf2 induction prevents ferroptosis in Friedreich's Ataxia. Redox Biol. 2021;38:101791. doi: 10.1016/j.redox.2020.101791. Go to original source... Go to PubMed...
  9. . Lecocq C, Charles P, Azulay JP, et al. Delayed-onset Friedreich's ataxia revisited. Mov Disord. 2016;31(1):62-69. doi:10.1002/mds.26382. Go to original source... Go to PubMed...
  10. Lee A. Omaveloxolone: First Approval. Drugs. 2023;83(8):725-729. doi: 10.1007/s40265-023-01874-9. Go to original source... Go to PubMed...
  11. . Lynch DR, Chin MP, Boesch S, et al. Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension. Mov Disord. 2023;38(2):313-320. doi: 10.1002/mds.29286. Go to original source... Go to PubMed...
  12. . Lynch DR, Chin MP, Delatycki MB, et al. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study). Ann Neurol. 2021;89(2):212-225. doi: 10.1002/ana.25934. Go to original source... Go to PubMed...
  13. . Paulasová Schwabová J, Danková M. Ataxie. Cesk Slov Neurol N. 2018;81/114(2):131-149. doi: 10.14735/amcsnn2018131. Go to original source...
  14. . Pilotto F, Chellapandi DM, Puccio H. Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia. Trends Mol Med. 2024;30(2):117-125. doi:10.1016/j.molmed.2023.12.002 Go to original source... Go to PubMed...
  15. . Rummey C, Corben LA, Delatycki MB, et al. Psychometric properties of the Friedreich Ataxia Rating Scale. Neurol Genet. 2019;5(6):371. doi: 10.1212/NXG.0000000000000371. Go to original source... Go to PubMed...
  16. . Vyhnálková E, Mušová Z, Zumrová A, et al. Dědičné cerebelární ataxie u dospělých. Neurol. praxi. 2019;20(5):344-350. doi: 10.36290/neu.2019.139. Go to original source...
  17. . Zumrová A, Šťovíčková L. Friedreichova ataxie. Cesk Slov Neurol N. 2024;6:385-401. ISSN 1803-6597. Go to original source...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.